$1.27
-0.10-7.3%
Last update: Nov 5, 9:08 AM

The average analyst price target for Aptevo Therapeutics is $106,560, 7778002.2% above the current price. The one analyst covering it rates it Buy. The latest change came on Sep 23, 2024, when Roth MKM lowered its price target on Aptevo Therapeutics from $199,800 to $106,560 and kept a Buy rating.
Price Target Range — 1 Quarters
Analyst Consensus — 1 Analysts
Rating Trend — Last 9 Months